Preclinical Efficacy of a Carboxylesterase 2-Activated Prodrug of Doxazolidine by Barthel, Benjamin et al.
Preclinical Efficacy of a Carboxylesterase 2-Activated Prodrug of
Doxazolidine
Benjamin L. Barthel§, Zhiyong Zhang‡, Daniel L. Rudnicki§, Christopher D. Coldren¡,
Margaret Polinkovsky¶, Hengrui Sun¶, Gary G. Koch¶, Daniel C.F. Chan‡, and Tad H. Koch§
§Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309
‡Department of Medical Oncology, University of Colorado Denver Health Sciences Center, Aurora,
CO 80045
¡Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver Health
Sciences Center, Aurora, CO 80045
¶Biometric Consulting Laboratory, Gillings School of Global Public Health, University of North
Carolina, Chapel Hill, NC 27599
Abstract
Doxazolidine (Doxaz) is a functionally distinct formaldehyde conjugate of doxorubicin (Dox) that
induces cancer cell death in Dox-sensitive and resistant cells. Pentyl PABC-Doxaz (PPD) is a prodrug
of Doxaz that is activated by carboxylesterase 2 (CES2), which is expressed by liver, non-small cell
lung, colon, pancreatic, renal, and thyroid cancer cells. Here, we demonstrate that in two murine
models, PPD was effective at slowing tumor growth and demonstrated markedly reduced cardiotoxic
and nephrotoxic effects, as well as better tolerance, relative to Dox. Hepatotoxicity, consistent with
liver expression of the murine CES2 homolog, was induced by PPD. Unlike irinotecan, a clinical
CES2-activated prodrug, PPD produced no visible gastrointestinal damage. Finally, we demonstrate
that cellular response to PPD may be predicted with good accuracy using CES2 expression and Doxaz
sensitivity, suggesting that these metrics may be useful as clinical biomarkers for sensitivity of a
specific tumor to PPD treatment.
Introduction
Doxorubicin (Doxa) is an anthracycline antitumor drug that functions primarily as a
topoisomerase 2 poison to induce cancer cell death.1,2 Doxazolidine (Doxaz, Scheme 1) is the
formaldehyde conjugate of Dox that induces cancer cell death independent of topoisomerase
2 by crosslinking DNA.3,4 Relative to Dox, Doxaz exhibits significantly enhanced toxicity
against a wide variety of tumor cell lines, including cell lines resistant to Dox, without increased
toxicity to rat cardiomyocytes.3 A long-standing goal in Dox research has been to minimize
the treatment-limiting, chronic, irreversible cardiotoxicity associated with Dox therapy.5 The
enhanced tumor selectivity of Doxaz results in an improvement of the theoretical therapeutic
index by 100- to 10,000-fold, depending on the cell line tested. The use of Doxaz as a
conventional chemotherapeutic agent is unlikely due to its short aqueous half-life of 3 min at
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37 °C (pH 7.4) and potent toxicity.4 Measurements by the Developmental Therapeutics
Program of the National Cancer Institute of the NIH (NCI-DTP) place the maximum tolerated
dose in mice at 0.3 mg/kg upon i.v. injection of a DMSO solution of doxoform (DoxF, Scheme
1), a dimeric prodrug of Doxaz that releases Doxaz with a half-life of approximately 1 min at
37 °C (pH 7.4).4 Further, in cell experiments DoxF exhibits statistically identical growth
inhibition as Doxaz.4,6 However, these very problems are elevated to advantages when prodrug
delivery of Doxaz is explored.
Prodrugs are inactive variants of active drugs which, when applied to chemotherapy, are
preferentially activated at sites that display properties of tumors or tumor stroma. While Dox
has already demonstrated significant preclinical potential from delivery as a prodrug,7 this
treatment approach benefits even more when the active drug is unstable and presented for only
a short period of time. In these cases, the active agent cannot easily be activated in one region
and attack a distant region before it degrades and loses much of its potency. Its instability and
potency make Doxaz an ideal candidate for prodrug delivery. Conceptual models for the design
of a Doxaz prodrug are capecitabine and irinotecan (Scheme 1) because they are both activated
by carboxylesterase-catalyzed hydrolysis of a carbamate functional group, and Doxaz is
stabilized with respect to hydrolysis by carbamylation of its oxazolidine nitrogen (Scheme 1).
8
Capecitabine is an enzymatically-activated prodrug that was developed to deliver 5-
fluorouracil (5-FU) orally.9 5-FU, a nucleotide base analog, is metabolized inside both normal
and tumor cells to produce active agents that inhibit the synthesis of thymidine triphosphate
and interfere with protein synthesis and RNA processing (reviewed in 10). Capecitabine was
first approved in 1998 as a first-line treatment for metastatic colorectal cancer. It is also
approved for metastatic breast cancer that is resistant to anthracycline treatments 11 and exhibits
a reproducibly better response rate over 5-FU as a single-agent.
Irinotecan was approved by the FDA in 1996 for the treatment of advanced colorectal cancer,
either in combination with 5-FU/lecovorin (LV) as a first-line treatment or alone as a second-
line treatment following recurrence or progression after 5-FU/LV treatment. Irinotecan was
designed as a water soluble delivery method for the camptothecin derivative SN-38, which is
released following enzymatic cleavage.12 First identified in a NCI screening protocol in
1966,13 camptothecin soon became recognized as a potent inhibitor of topoisomerase 1.14,15
Release of the active agents from the prodrugs is accomplished, in part, by the carboxylesterase
(CE) enzymes CES1 and CES2, members of a class of endoplasmic-reticulum-bound
hydrolases normally implicated in xenobiotic detoxification.9,16–18 Targeting to the enzyme
is accomplished by the presence of a hydrophobic group, to which the active agent or an
inactivating substituent is linked by way of a carbamate moiety (Scheme 1), and hydrolysis of
the carbamate results in the release of either SN-38 directly or 5’-deoxy-5-fluorocytidine,
which is further processed by two more metabolic enzymes to 5-FU.
The prodrug of Doxaz, pentyl PABC-Doxaz (PPD, Scheme 1), is a pentyl carbamate bearing
a Katzenellenbogen spacer 19 to separate the enzyme active site from the active drug and reduce
steric hindrance.8 Experiments with recombinant CES1 and CES2 indicate that PPD is
predominantly activated to Doxaz by CES2.20 The results of cell-free enzyme experiments are
consistent with a correlation of carboxylesterase expression by Western blot with PPD cell
growth inhibition. Of particular relevance, rat cardiomyocytes show low expression of CES2
and low growth inhibition, suggesting low potential for cardiotoxicity.20 These findings
prompted preclinical in vivo evaluation of PPD in mouse xenograft models using cancer cells
that express significant levels of CES2.
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Pentyl PABC-Doxaz (PPD) displays potent in vitro toxicity against cells expressing CES2 and
is, therefore, likely to slow the growth of a tumor derived from CES2-expressing cells. Results
of previous experiments identified N-Hep G2 hepatocellular carcinoma (HCC) cells as
expressing high levels of CES2 in a Western blot analysis and responding to treatment with
PPD in a growth inhibition assay.20 To identify a second cancer cell line of a different type
that could be used in a xenograft experiment, a panel of non-small cell lung cancer (NSCLC)
cells were screened for expression of CES2 mRNA. As shown in Figure 1, H1435 NSCLC
cells expressed the highest levels of CES2. Growth inhibition measurements (also Figure 1)
indicated that these cells also responded well to treatment with PPD; the response (log IC50 =
−6.92) was very similar to the response of N-Hep G2 cells (log IC50 = −6.90). Another
promising NSCLC cell line indicated by the results in Figure 1 is H460. This cell line also
responded well in the National Cancer Institute 60-cell screen of PPD (log GI50 = −6.35, mean
of two determinations).
Animal Studies with PPD
To demonstrate efficacy in an animal model, N-Hep G2 liver cancer and H1435 non-small-
cell lung cancer cells were implanted subcutaneously into immunocompromised mice, which
were then treated with either Dox or various concentrations of PPD by tail-vein injection.
Treatments were initially given as three weekly injections, starting one week after implantation.
Subsequent treatments were then performed to measure the efficacy of the drugs at slowing
the growth of a rapidly growing tumor.
When N-Hep G2 cells were implanted subcutaneously into NOD/SCID mice, the resulting
tumors, if untreated, grew quickly as shown in Figure 2. Tumor growth was strongly inhibited
by treating the mice with Dox or the higher dosages of PPD, while 3 mg/kg PPD (Dox equiv
weight) had no effect. However, when the mice in the 3 mg/kg group were treated with 5 mg/
kg PPD on days 45 and 52, the rate of tumor growth was slowed, eventually resulting in an
average tumor size nearly identical to those found in the higher dose PPD groups. While Dox
had the greatest antitumor effect, it also had the greatest toxicity; 70% of the mice in the
treatment group had died by the end of the study (Figure 2). By comparison, all 10 mice
survived in the 5 mg/kg PPD group and 9 survived in the 4 mg/kg PPD group. Prior to redosing,
3 mg/kg PPD was well tolerated; after the mice were retreated with 5 mg/kg, however, 60%
of the mice were lost by the end of the study.
Body weight changes were monitored during the first 5 weeks of the experiment. Mice treated
with 3 and 4 mg/kg PPD (Dox equiv weight) showed similar weight changes relative to no
drug control mice. However, mice treated with 5 mg/kg showed 18% weight loss at 3 weeks
recovering to 10% at 5 weeks. Dox treated mice showed the most severe weight loss, 23% at
4 weeks recovering to 14% at 5 weeks.
As stated earlier, another cell line that responded well in tissue culture IC50 experiments is the
non-small cell lung cancer line H1435 (Figure 1). Cells were subcutaneously implanted into
nude mice and treatment started as before, with tail vein injections of either Dox (2.5 mg/kg)
or PPD (3 mg/kg or 4 mg/kg Dox equiv weight) on days 7, 14, 21 and retreatment of all groups
on days 56, 63, and 70. Shown in Figure 3, tumors were most significantly affected by treatment
with the higher dose of PPD, while 3 mg/kg PPD and 2.5 mg/kg Dox produced similar results.
Retreatment of the tumors produced a leveling effect on tumor growth in the PPD groups but
not the Dox group, suggesting that perhaps the Dox-treated tumors had developed insensitivity
to Dox treatment. In this experiment, all mice in all groups survived the duration of the study.
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During the course of the experiment, two mice in the treatment groups had unplanned
pregnancies and delivered healthy babies. This precluded body weight measurements. A
treatment limiting side effect of irinotecan therapy is diarrhea because CES2 is also expressed
by normal as well as cancer cells in the colon. Further, SN-38 produced in the liver is detoxified
by glucuronidation in the liver and excreted to the colon via the bile duct where it is reformed
by beta-glucuronidase.21 No evidence of diarrhea appeared in either of the mouse experiments
reported here.
Statistical analysis through a repeated measures mixed model for the growth of the H1435
tumors in response to treatment indicated that all treatment groups were significantly different
from the untreated group over the entire course of the experiment. This model had invocation
for the cubed root of tumor size as that represented the radius for a sphere of the same size in
order to have more homogeneous patterns of variability at the respective days of assessment,
and it had covariance adjustment for day 7 so as to control for tumor size at the start of treatment.
For the experiment as a whole, PPD dosed at either 3mg/kg or 4mg/kg did not show statistically
significant reductions in tumor size, as compared to 2.5mg/kg Dox. However, there were
significant differences between these PPD doses and 2.5mg/kg Dox for the change in tumor
size from days 14 to 28 as an average to days 63 to 77 as an average. In this regard, during the
first 5 weeks of the study, which includes the 3 initial treatments and two recovery weeks, PPD
dosed at 4mg/kg was much better than treatment with Dox (p= 0.0002), and it was also better
than PPD at 3mg/kg (p=0.001) and control (p<0.0001). This indicates that, during the active
treatment, PPD is better than Dox at inhibiting tumor growth. Later treatments with 4 mg/kg
PPD did not slow tumor growth any better than did 2.5 mg/kg Dox, suggesting that the tumors
had adapted during the period from days 21 to 56 to a state in which they were less sensitive
to PPD. Since we have never observed a cell line that has developed Doxaz resistance, it seems
likely that modulation of the CES2 expression was the mechanism of adaptation. Given the
success of PPD over the initial active treatment, however, early and regular treatments show
great potential for significant antitumor effect, above those that can be achieved by Dox.
The successful antitumor activity of PPD in this animal model indicates that expression of
CES2 in the tumor tissue or stroma may serve as a biomarker for prediction of tumor response
to PPD. This status as a biomarker has been conferred upon CES2 previously in regard to
success of irinotecan treatment 22 and may be applicable here. This is important because
customized and tailored chemotherapeutic regimens, which are directed specifically at
properties of the tumor or tumor stroma, may represent the best chance for successful induction
of tumor remission in the clinic. Therefore, the identification of a biomarker for success of
PPD treatment is a significant addition that provides the basis for future inclusion of PPD in
these regimens.
Histological Examination of Tissues
Dox treatment induces a cumulative cardiotoxicity, manifested as vacuolar degeneration of the
myocytes and, eventually, necrosis (review23). Although the cardiotoxicity is generally
considered the dose-limiting side effect, Dox negatively affects the structure and function of
other tissues. Metabolism of Dox in the liver results in hepatotoxic effects. Liver biopsies taken
shortly after Dox administration indicate that infiltration of inflammatory cells and steatosis,
the accumulation of lipid droplets in hepatocytes, can be indicative of acute Dox hepatotoxicity.
24,25 Other damages observed include focal damage to hepatocytes, damage to the vascular
structure, and cytoplasmic vacuolization, although many of these effects were induced by Dox
injected intraperitoneally at dosages well above the i.v. doses given here.24–26 In the kidney,
Dox toxicity is manifested histologically as congestion and degeneration of the convoluted
tubules and glomerular damage, such as widening of Bowman’s capsule and capillary dilation.
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27–29 These effects are likely a result of lipid peroxidation and reactive oxygen species
production, similar to the mechanisms of Dox cardiotoxicity.30–33
A predicted outcome of prodrug treatment is that only those cells capable of activating the
prodrug will be exposed to the toxic product. Those tissues that lack the activating enzyme will
only see the inactive precursor. As CES2 is involved in the detoxification of drugs, it is therefore
not surprising that human liver expresses moderate levels of CES2. Similarly, the mouse
homolog of CES2, mCES2, is expressed in murine liver.34 Therefore, as a measure of
comparative toxicity to treatment with Dox, cardiac, hepatic, and kidney tissues were taken
from nude mice in the non-small cell lung cancer model above. Additionally, since the CES2-
activated clinical prodrug irinotecan is noted for its gastrointestinal toxicity, the ileum was also
collected for analysis. Paraffin-embedded sections from these tissues were stained with
hematoxylin and eosin to observe the cellular and tissue morphology.
Cardiac tissue from control, tumor-bearing mice appeared healthy, demonstrating well-
organized myofibrils with clear interstitial spaces (Figure 4). In contrast, treatment of mice
with six i.v. injections of 2.5 mg/kg Dox resulted in extensive myofibril disorganization and
severe levels of vacuolization. Regions of cardiomyocyte necrosis were also visible. Further,
fibrotic damage was indicated by elevated pink staining in the interstitial spaces, suggesting
the presence of collagen. Hearts of mice treated with PPD showed many fewer signs of
cardiotoxic effects, exhibiting low-grade, dose-dependent vacuolization and few to no fibrotic
regions.
Like cardiac tissue sections, the hepatic tissue sections of the control mice demonstrated a
healthy appearance (Figure 5). Low magnification (top panel) revealed well-formed cords of
hepatocytes, separated by well-defined sinusoids. At higher magnification (lower panel), the
hepatocytes were seen to be stained in a fairly uniformly-distributed punktate-like pattern. A
similar pattern was seen for livers from mice treated with 2.5 mg/kg Dox. Little significant
difference was noted between Dox and control livers, with the former lacking the periportal
hepatocyte damage and disorganization that has been described at higher dosages.24 Treatment
of mice with PPD, however, did result in some evidence of hepatotoxicity. A dose-dependent
decrease in the uniformity of the punktate staining pattern likely indicates a cytoplasmic
buildup of lipid deposits, a possible result of lipid peroxidation by the Dox and Doxaz resulting
from prodrug activation. Low magnifications indicated a progression in the severity of damage,
from most significant in the periportal regions and decreasing slightly towards the central vein
of the classical lobule.
Interestingly, while all liver tissue examined appeared similar for the control, Dox, and 3 mg/
kg PPD groups, one of the liver sections from the 4 mg/kg PPD group had a very different look
from others in the group of four examined. Shown in Figure 6, sections from this liver had a
more typical “fatty-liver” appearance, which is manifested as large spherical deposits of lipids,
sometimes engulfing the majority of the cell body. Outside the large deposit, the remaining
parts of the hepatocyte exhibited a more normal staining pattern. Perhaps this state represents
an earlier stage in the hepatotoxic profile of PPD.
As in cardiac tissue, kidney tissue from mice treated with 2.5 mg/kg Dox exhibited many more
toxic effects than control tissue (Figure 7). Degeneration of the tubules due to vacuolar damage
was evident, as was congestion of the convolute tubules. By contrast, tissues from mice treated
with the prodrug were less affected; there was no vacuolar degeneration in the tissues and
infrequent regions of tubular congestion were present in a dose-dependent manner. The higher
dose of PPD also resulted in a thickening of Bowman’s capsule in a small subset of glomeruli.
In contrast to irinotecan, which has been shown in the literature to induce severe morphological
degradation and destruction of gastrointestinal tissues,35,36 treatment of mice with PPD
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resulted in no visible damage to the ileum (Figure 8). All four treatment groups demonstrated
healthy villi and support structures, with no vacuolar damage or inflammatory cell infiltration.
This information, combined with the results of the treatments on tumor size, clearly indicate
that PPD is a better treatment for CES2-expressing human tumors in these mouse models.
Dosages that result in statistically identical inhibition of tumor growth (2.5 mg/kg Dox and 3
mg/kg PPD) resulted in very different cardiotoxicity profiles. Treatment with Dox was, as
expected, much more cardiotoxic than treatment with the prodrug, likely contributing to the
better tolerance for the prodrug in the less-hardy NOD/SCID mice used in the HCC model.
Although PPD produces greater hepatotoxicity at the cellular level than Dox at equipotent
dosages, the regenerative potential of the liver is likely to minimize any detrimental effects of
PPD on overall liver function, unless treatment continues over a very long period of time. In
a clinical setting, the most significant treatment-limiting side effect of Dox is the cardiotoxicity,
an effect that is clearly reduced by treatment with the prodrug. A further encouraging
observation for development is the stability of PPD in human plasma versus mouse plasma.
Hydrolysis experiments show PPD to be 75% stable in pooled human plasma at 37 °C over a
24 h period but only 16% stable in mouse plasma over a 24 h period, hence the possibility of
better efficacy in humans than in tumor bearing mice. Instability of irinotecan in rodent blood
is well documented.37–39 Possible applications where CES2 expression has been identified in
human tumor tissue include liver, pancreatic, kidney, colon, and thyroid cancer.40 Liver and
pancreatic cancers are of particular relevance because of limited treatment options and poor
prognosis.
Drug Sensitivity of NCI 60-Tumor Panel
To assess the efficacy of PPD and Doxaz against a wide array of cancer types, they were
submitted to the National Cancer Institute Developmental Therapeutics Program
(http://www.dtp.nci.nih.gov/) for testing against their panel of 60 human tumor cell lines.
Doxaz was delivered as its dimeric form, Doxoform, which degrades quickly to two molecules
of Doxaz and results in growth inhibition values that are equivalent within experimental error.
4 The panel contains tumor cell lines from leukemia, non-small cell lung, colon, central nervous
system, melanoma, ovarian, renal, prostate, and breast origin. The raw growth data for Doxaz
and PPD (provided in Supporting Information) was reprocessed by non-linear least-squared
analysis, fitting to a variable-slope dose response curve to produce IC50 values for each cell
line, while growth data for Dox was pooled from more than 1900 measurements. Over each
tumor type tested, Doxaz was more toxic than Dox by between 1 to 2 orders of magnitude
(Figure 9A and B). PPD produced growth inhibition values that ranged from greater than 100
µM (log IC50 = −4) to less than 25 nM (log IC50 = −7.6) and averaged, across all tumor lines,
about 18 µM (log IC50 = −4.7; Figure 9C).
Since PPD is activated to Doxaz by endogenously expressed CES2, the results for PPD
sensitivity should be examined with respect to CES2 expression. Therefore, microarray data
for CES2 expression in each cell line in the panel were gathered from experiments deposited
with the NCI Developmental Therapeutics Program. As shown in Figure 9D, expression of
CES2 tends to be quite variable, not only between tumor types but also within a single type.
This is not surprising, given that literature reports suggest that expression of CES2 in human
tumors tends to correlate poorly with tumor types, location, or progression.40 However,
similarly to Figure 1, those cell lines which show higher CES2 expression, such as the subset
above 2.4 in Figure 9D, tend to demonstrate a better response to treatment with PPD; the cells
in this subpopulation (H460, HCC-2998, SW-620, SK-OV-3, A498, ACHN, SN12C, TK-10,
and UO-31) had an average PPD IC50 that was greater than 17-fold lower than the average
IC50 of the rest of the cells in the panel. Additionally, the tissue type with the greatest
contribution to the high-CES2 population is the renal panel, which also displays the lowest
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average PPD IC50 of any tissue type. Therefore, very high CES2 is a good predictor for high
sensitivity to PPD treatment and, as stated above, may be useful as a biomarker for in vivo
PPD treatment success.
Multiple Regression Analysis of NCI 60-Tumor Panel
While the likelihood of a cell line or population exhibiting high sensitivity to PPD is increased
by high CES2 mRNA, many cells do not fit the above simplistic model. For example, Figure
9 demonstrates that the leukemia panel exhibits a better-than-average response to PPD with
lower-than-average CES2 expression, indicating that, to predict PPD response, more
information than simply CES2 expression must be taken into account. Since PPD is poorly
active in cells with low expression of CES2,20 the ultimate effector of cellular toxicity is the
product of PPD activation, Doxaz. Therefore, response to PPD depends not only on the level
of the activating enzyme present in the cells, but also the innate cellular sensitivity to Doxaz.
To determine the contributions of CES2 and Doxaz on PPD sensitivity, a multiple regression
analysis (SAS version 9.1.3) was made using a General Linear Model in which the average of
the log of the PPD IC50 is directly proportional to the log of the Doxaz IC50 and inversely
proportional to the log of CES2 expression, as measured by mRNA microarrays. This analysis
resulted in the equation shown in Table 1 and the full analysis is presented in Supporting
Information. The quality and significance of the fit were very good, indicated by a P value of
less than 0.0001. The term C3, which is constant for all cells, likely indicates a common physical
component, such as the diffusion of PPD across the plasma membrane and the accessibility of
CES2 within the endoplasmic reticulum.
This equation allows for a more refined prediction of cellular response to PPD, as shown in
Figure 10. Also, it explains the behavior of cells and populations which contradict the simplistic
model of sensitivity based solely upon CES2 expression. In the case of the leukemia panel
discussed above, the cells express lower-than-average levels of CES2 but are intensely affected
by very low Doxaz concentrations. Therefore, the small amount of Doxaz produced by their
endogenous CES2 activity is enough to produce the greater-than-average response to PPD in
these very Doxaz-sensitive cells. The model also indicates that a log change in CES2 expression
is greater than 6-fold more influential to the PPD response than a log change in Doxaz IC50.
We feel that this indicates the ability of CES2 to convert multiple units of PPD into Doxaz.
Given that the rate of conversion is quite slow,20 it is unlikely that enough prodrug is hydrolyzed
to significantly affect the kinetics of activation. Therefore, more enzyme is able to produce a
consistently higher concentration of Doxaz, resulting in a greatly increased cytotoxic effect
over the 2-day duration of the treatment. Finally, this model highlights further potential for
PPD to be a successful clinical drug; neither high CES2 expression nor high Doxaz sensitivity
is necessary, but both are sufficient for a cell line to respond well to PPD treatment. Therefore,
either metric has the potential to be used as a marker for in vivo success.
Summary and Conclusions
PPD, the CES2-activated prodrug of Doxaz, effectively inhibited the growth of a subcutaneous
human hepatocellular carcinoma xenograft and a subcutaneous human NSCLC xenograft on
immuno-compromised mice relative to a no drug control. Both of the cell lines used to create
the xenografts were shown to express high levels of CES2. Growth inhibition of the NSCLC
xenograft by 4 mg/kg PPD was shown to statistically exceed that of 2.5 mg/kg Dox during the
first 5 weeks of the experiment which included the initial three-dose treatment period. Tissue
analyses showed significantly less evidence of cardiotoxicity and nephrotoxicity from
treatment with PPD than from treatment with Dox. PPD showed more hepatotoxicity consistent
with expression of CES2 in normal liver cells. Further evidence for activation of PPD to Doxaz
in cancer cells was obtained through correlation of PPD-induced inhibition of growth of the
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60 human cancer cells in the NCI screen with Doxaz growth inhibition and expression of CES2
using multiple regression analysis. CES2 expression and response to Doxaz may be useful
biomarkers for the efficacy of PPD treatment. Significant tumor growth inhibition in the mouse
xenograft experiments is particularly encouraging for further development of PPD given its
low stability in mouse plasma versus high stability in human plasma.
Experimental Methods
1. Reagents
Doxorubicin hydrochloride was from a clinical sample manufactured by Bedford Laboratories
(Bedford, OH) that contained 20 mg of doxorubicin hydrochloride and 100 mg of lactose.
Prilled Paraformaldehyde was purchased from Sigma Aldrich (Milwaukee, WI). D5W was
from B. Braun Medical (Irvine, CA) and dimethyl sulfoxide (DMSO) was from Burdick and
Jackson (Muskegon, MI).
2. Synthesis of Pentyl PABC-Doxaz (PPD)
The original method for synthesis of the Doxaz prodrug pentyl PABC-Doxaz (PPD) was
reported previously.8 However, improvements in the synthesis of Doxaz, which is then used
in the synthesis of PPD, are reported here. Expired clinical samples of Dox (20 mg) were
provided as lyophilized pellets containing 100 mg lactose monohydrate. The pellet was
dissolved in 15 mL saturated sodium bicarbonate (pH ~8.3) and extracted into 50 mL
chloroform per 5 Dox samples, each performed individually. The resulting fluffy interface
emulsion and the aqueous layer were separated. The aqueous layer was extracted twice more
into 50 mL fresh chloroform. The emulsion was diluted with an equal volume of saturated
sodium bicarbonate and extracted into an equal volume of chloroform. All chloroform fractions
were combined and dried over sodium sulfate, filtered, and rotary evaporated to dryness. The
Dox free base was thoroughly dried under high vacuum (10−2 Torr) for a minimum of 2.5 h.
Yield was 97%, as measured by optical density in 50% water, 50% DMSO, using a molar
extinction coefficient of 11,500 M−1 cm−1. Dox free base (100 mg, 0.18 mmol) was dissolved
in deuteriochloroform (Cambridge Isotope Laboratories, Andover, MA) and 1.1–2.0 equiv of
prilled paraformaldehyde added. The reaction was stirred at room temperature under an argon
atmosphere and monitored by 1H-NMR for completion, typically occurring after 2–3 days.
NMR data were reported earlier.4 The amount of paraformaldehyde added determines the ratio
of Doxaz to its dimeric form, Doxoform (DoxF), since Doxaz reacts with an additional equiv
of formaldehyde to produce DoxF. The reaction mixture, when complete, was filtered and the
solvent rotary evaporated. The resulting red solid was dried overnight under high vacuum
(10−2 Torr). The product, 65–90% Doxaz, 35-10% DoxF, was not further purified, since DoxF
degrades to produce two units of Doxaz, and was recovered in 98% yield. All remaining steps
required to make PPD and their resulting yields and purity (>95% by HPLC and 1H NMR)
were identical to those described previously.8
3. Cells
N-Hep G2 cells were obtained from Dr. Barbara Knowles at the Jackson Laboratories (Barr
Harbor, ME). All the NSCLC cells were obtained from the Colorado SPORE-Lung Program
(Paul Bunn, Jr., University of Colorado Denver, Aurora, CO). These lines were maintained in
RPMI media supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone,
Logan, UT).
4. Cell Experiments
Inhibition of cell growth by PPD or doxorubicin was assessed using a modified tetrazolium
salt (MTT) assay.41 Briefly, 2000–4000 viable cells were plated in 100 µL of growth medium
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in 96-well plates (Corning, Ithaca, NY) and incubated overnight at 37 °C in a humidified
incubator under an atmosphere of 95% air, 5% CO2. PPD was added at various concentrations
and the plates were incubated for 5–6 days. The tetrazolium salt (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide, Sigma Aldrich) was dissolved in RPMI to a
concentration of 4 mg/mL, sonicated, and immediately added to the cells for a final
concentration of 0.4 mg/mL. The medium was aspirated after 4 h and the reduced MTT product
was solubilized by adding 100 µL of 0.2 N HCl in 75% isopropyl alcohol, 25% milliQ water
(Millipore, Inc., Billerica, MA) to each well. Thorough mixing was done using a Titertek multi-
channel pipetman. The optical density of each well was measured using an automated plate
reader (Molecular Devices, Sunnyvale, CA). Absorbances for treated wells were normalized
with the vehicle control and plotted to obtain the IC50 values for each cell line
5. Microarray Analysis of Gene Expression
Microarrays were run using RNA isolated from untreated (baseline) NSCLC cell lines growing
in culture. RNA stabilization, isolation and microarray sample labeling were carried out using
standard methods for reverse transcription and one round of in vitro transcription.42 HG-U133
set microarrays were hybridized with 10 µg cRNA and processed per the manufacturer’s
protocol (Affymetrix, Foster City, CA). Individual arrays were determined to be of high quality
by visual inspection, comparison of the overall fluorescence intensity (scaling factor) to other
arrays in the group, and low 3’/5’ ratios for GAPDH and β-Actin (ratio < 3). This procedure
insures that each of the arrays in the group can be directly compared, and that the input mRNA
was intact. Hybridization signals and detection calls were generated in BioConductor, using
the “Robust Multi-Array Average” (RMA) expression measure.43 This expression dataset has
been deposited in the NCBI Gene Expression Omnibus and is publicly available as accession
GSE4342.
6. NOD/SCID N-Hep G2 Xenograft Mouse Model
The in vivo efficacy of PPD, relative to Dox, was initially measured against tumors derived
from N-Hep G2 cells in NOD/SCID mice. NOD/SCID mice (4–6 week old females) obtained
from the Jackson Labs (Barr Harbor, ME) were maintained in accordance with UCHSC
institutional guidelines using an approved IACUC protocol. N-Hep G2 cells (~1.5 × 107 per
mouse) were injected subcutaneously in the left flank, and i.v. injection via the tail vein of
vehicle, 3 mg/kg Dox, 3 mg/kg PPD Dox-equivalent weight, 4 mg/kg PPD Dox-equivalent
weight, or 5 mg/kg PPD Dox-equivalent weight (10 mice group) began one week after cell
implantation. Control mice received the delivery vehicle only. PPD or Dox was dissolved in
50 µL of DMSO, to which 950 µL of isotonic water/5% dextrose (D5W) was added
immediately prior to injection of 100 µL per mouse. Three rounds of injections were performed,
spaced by one week each. Approximate tumor volumes (π × short diameter2 × long diameter /
6) and animal body weight were measured weekly. To determine whether the drugs were
capable of slowing the growth of large, rapidly growing tumors, mice in the 3 mg/kg PPD
group were treated with 5 mg/kg PPD at days 45 and 52.
7. Stability of PPD in Mouse and Human Plasma
To test for the presence of prodrug-activating activity in the plasma of NOD/SCID mice, 10
µL of a 1 mM DMSO stock solution of PPD was diluted in 190 µL of mouse plasma from
healthy mice (thawed from flash frozen stock) and incubated at 37 °C. Aliquots (90 µL) were
removed at 0 and 24 h. Proteinase K (2 mg/mL) was added and the reaction incubated at 37 °
C for an additional 4 h to avoid incorporating PPD and/or Dox into the precipitated protein,
thereby masking it from inclusion in the analysis. PPD was stable to 2 mg/mL proteinase K
for 24 h. Following incubation of the prodrug in plasma with proteinase K, the solution was
analyzed by C-18 reverse phase HPLC (Agilent 1050/1100 instrument, Santa Clara, CA, with
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Agilent 4.6 mm i.d. × 15 cm column with 5 µm, C18 packing) eluting with a gradient of 20
mM triethylammonium acetate pH 6.0 buffer with acetonitrile starting at 80% buffer, isocratic
to 1 min, to 60% buffer at 5 min, to 20% buffer at 10 min, isocratic to 17 min and detecting at
480 nm. Stability in pooled human plasma from 40 normal individuals (thawed from flash
frozen stock, SomaLogic, Inc., Boulder, CO) was similarly determined.
8. Nude Mouse H1435 Xenograft Model
As an additional measure of the antitumor efficacy of PPD, its activity was tested against
subcutaneous tumors of H1435 cells, a non-small cell lung cancer (NSCLC) line that responded
well by in vitro growth inhibition assays. Athymic nude mice (4–6 week old females) obtained
from the National Cancer Institute (Bethesda, MD) were maintained in accordance with
UCHSC institutional guidelines using an approved IACUC protocol. H1435 cells were injected
into the left flank of each mouse (~2 × 106) at day 0. Owing to the potent systemic toxicity of
Dox treatment in the NOD/SCID experiment, the dosage of Dox was reduced for this study.
Treatment groups were control, 2.5 mg/kg Dox, 3 mg/kg PPD Dox-equivalent weight, and 4
mg/kg PPD Dox-equivalent weight (10 mice/group). Three i.v. injections were given, separated
by a week, starting one week after implantation. As before, the tumor volume was determined
by caliper measurement and calculated by the formula: π × short diameter2 × long diameter/6.
Due to the unplanned pregnancies of two mice, body weight measurements were not recorded.
Retreatment of all groups was performed on days 56, 63, and 70.
9. Statistical analysis of H1435 tumor growth inhibition
The data have the structure of longitudinal repeated measurements with equal sample sizes of
10 for each of the 11 time points for each treatment. Tumor size was calculated so that the cube
root represented the radius for the sphere of the same size. The cube roots of the tumor size
were analyzed since they had reasonable homogeneity of variance at each point of time for
assessment. Since the tumor size measured at day 7 was not affected by treatment, it served as
a baseline covariate in the model for tumor size at the beginning of treatment.
The mixed model was used to produce the results for the repeated measurements for the entire
course of the experiment.44 Although the covariance structure in the model should be
unstructured (UN), 10 time points for post-treatment assessment is excessive for an overall
sample size of 40. In accordance with the study design, an appropriate way to perform the
analysis is to partition the entire study into three periods (day 14–28, day 35–56, day 63–77)
with these representing the beginning, middle and the end of the study. An average was
calculated within each period, and so the number of quantities analyzed was reduced to what
can be managed by the model. The pattern of treatment differences across three periods has
analysis through the model including effects for treatments, periods, treatment × period
interaction and day 7 as baseline. This model enabled assessment of overall differences among
treatments through the weighted mean of treatment differences across the three periods. It also
enabled assessment of heterogeneity of treatment differences across the periods (i.e., treatment
× period interaction) through treatment comparisons for the difference between the last period
and the first period. Since such heterogeneity was significantly evident (p<0.001), treatment
comparisons within each period can have separate assessment through the model. SAS 9.1.3
(SAS Institute, Inc., Cary, NC) was used in conducting all the analysis.
10. Histology
Mice from the second study (H1435 cells into nude mice) were sacrificed by CO2/cervical
dislocation. Hearts, livers, kidneys, and sections of the ileum were recovered and fixed in 10%
formalin for 24 h. The tissues were embedded in paraffin blocks by the University of Colorado
Histology Core facility (Aurora, CO). Tissue sections 4 µm thick were cut and mounted onto
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glass microscope slides coated with 3-aminopropyltriethyoxysilane (APES; Sigma Aldrich,
St. Louis, MO) according the manufacturer’s instructions.
The mounted sections of heart and liver tissues were placed into an oven at 60 °C for 2 h to
melt the wax and deparaffinized by soaking in xylenes (10 min, 2 changes), 100% ethanol (5
min), and 95% ethanol (5 min). They were then rinsed in distilled water (5 min) and stained
in hematoxylin stain (Mayer’s, Sigma Aldrich) for 2 min. The stained slides were washed in
tap water (30 sec) and 1% ammonium hydroxide (5 dips × 1 sec), followed by distilled water
(2 min). They were dehydrated in 95% ethanol (5 min) and counterstained with Eosin
Yellowish Stain (30 sec, Thermo Fischer Scientific, Waltham, MA). The slides were rinsed in
95% ethanol (1 min), 100% ethanol (2 min, 2 changes), and xylenes (15 min, 2 changes).
Coverslips were applied with Permount (Daigger Inc., Vernon Hills, IL).
Kidney and ileum tissues were deparaffinized by 2 changes of xylene (2 min each) and
rehydrated with 1 min soaks in ethanol (100%, 2 changes, 95%, 70%), followed by deionized
water (1 min). The slides were stained in Harris hematoxylin (Anatech LTD, Battle Creek, MI)
for 50 sec. The slides were washed in deionized water (20 sec) followed by two washes of tap
water (20 sec each) and five dips into Scott’s Water (1% MgSO4, 0.2% NaHCO3). The tissues
were washed with tap water (2 × 20 dips) and dehydrated in 70% ethanol (20 dips). The slides
were counterstained with Eosin Y (Anatech, 3 dips) and rinsed with 2 changes of 95% ethanol
(6 dips, 12 dips) and 2 changes of 100% ethanol (12 dips, 15 dips). The stained tissues were
dehydrated with 2 changes of xylene (20 dips) and coverslips mounted with Richard-Allen
Mounting Medium (American MasterTech, Lodi, CA).
11. NCI 60-Tumor Panel
Doxoform, synthesized as described previously and equivalent to Doxaz with respect to
toxicity,4 and pentyl PABC-Doxaz were supplied as solid material to the Developmental
Therapeutics Program at the NCI. Following their analysis, raw cell growth data for both
compounds (NSC numbers 699940 and 741302 for Doxoform/Doxaz and PPD, respectively)
was extracted and reprocessed to fit the data to a variable-slope sigmoidal dose-response curve
(as opposed to the point-to-point method used by NCI) in GraphPad Prism version 4.0 software
(GraphPad Software, Inc., La Jolla, CA). The raw growth data are shown in Supporting
Information. As a comparison to both drugs, data for Dox (NSC 123127) were gathered. CES2
expression data were gathered on the basis of 1) Affymetrix U133 series chips, which were
used in the NSCLC panel above and 2) multiple experiments by the same lab. With these
selection criteria, data for six microarrays were collected: Pattern ID numbers GC174516,
GC178011, GC168722, GC228167, GC228168, and GC224427. Multiple regression analysis
was performed using SAS version 9.1.3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Gene transcription array for carboxylesterase 2 with a panel of non-small cell lung cancer cells
(NSCLC) and cellular response to pentyl PABC-Doxaz (blue and red, respectively). H1435
cells (center) show the highest CES2 expression and best response to the prodrug.
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Primary liver tumor xenograft growth inhibition and mouse survival as a function of i.v. dose
of PPD with 10 NOD/SCID mice per group. Treatment started 7 days after implantation of N-
Hep G2 liver cancer cells in mice (left flank). Doses are in mg/kg of doxorubicin equivalent
weight. Drug delivery vehicle was 5% DMSO/95% D5W. Control mice received drug delivery
vehicle. All 50 mice developed tumors. Mice were treated on days 7, 14, and 21; mice in 3 mg/
kg PPD group were redosed at 5 mg/kg on days 45 and 52. Error bars represent one standard
deviation.
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Non small cell lung tumor xenograft growth inhibition as a function of i.v. dose of PPD vs Dox
with 10 nude mice per group. Treatment started 7 days after implantation of H1435 NSCLC
cells (left flank). Doses are in mg/kg of doxorubicin equivalent weight. Drug delivery vehicle
was 5% DMSO/95% D5W. Control mice received drug delivery vehicle. All 40 mice
developed tumor. Mice were treated on days 7, 14, 21, 56, 63 and 70. All mice survived to
termination. Error bars represent one standard deviation.
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Micrographs of hematoxylin/eosin stained heart sections as a function of treatment as shown
in Figure 3. Hearts from nude mice receiving no drug appeared healthy, demonstrating well-
organized myofibrils and clear interstitial spaces. In contrast, treatment with six i.v. injections
of 2.5 mg/kg Dox resulted in extensive myofibril disorganization, accompanied by high levels
of vacuolization (examples shown with arrows) and regions of cardiomyocyte necrosis (stars).
Additionally, fibrotic damage was indicated by the increased presence of pink-stained
interstitial spaces. Treatment of mice with PPD resulted in significantly less cardiotoxic
indications with low-grade, dose-dependent vacuolar damage (arrows) and little to no fibrotic
regions. The bars represent 50 µm.
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Micrographs of hematoxylin/eosin stained liver sections as a function of treatment as described
in Figure 3. Like cardiac tissue sections, the hepatic tissue sections of the control mice
demonstrated a healthy appearance. Low magnification (top panel) revealed well formed cords
of hepatocytes, separated by well defined sinusoids. At higher magnification (lower panel),
the hepatocytes stained in a fairly uniformly distributed punktate-like pattern. A similar pattern
was seen for livers from mice treated with 2.5 mg/kg Dox. Little significant difference was
noted between Dox and control livers, with the former lacking the periportal hepatocyte damage
and disorganization that has been described at higher dosages. Treatment of mice with PPD,
however, did induce some evidence of hepatotoxicity. A dose-dependent decrease in the
uniformity of the punktate staining pattern likely indicates a cytoplasmic buildup of lipid
deposits, a possible result of lipid peroxidation by the Dox and Doxaz resulting from prodrug
activation. Low magnifications indicated a progression in the severity of damage, from most
significant in the periportal regions (P) and decreasing slightly towards the central vein (C) of
the classical lobule. The bars in the upper panels represent 100 µm and those in the lower panels
show 25 µm.
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Periportal regions from one mouse treated with 4 mg/kg PPD displayed classical steatosis in
the hematoxylin/eosin stained hepatocytes (arrows). The bar represents 120 µm.
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Micrographs of hematoxylin/eosin stained kidney sections as a function of treatment as
described in Figure 3. Tissue from control mice is healthy, exhibiting well-formed tubules,
glomeruli, and cells. Treatment with 2.5 mg/kg Dox resulted in the appearance of a vacuolar-
like damage (asterisks) and hyaline deposits in a subset of tubules (triangle). Neither prodrug
treatment resulted in visible cellular damage, although a dose-dependent congestion of tubules
with hyaline deposits (triangles) was evident. Additionally, the higher dose of PPD induced a
thickening of Bowman's capsule in a small population of glomeruli, as shown on the right. The
bar indicates 200 µm.
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Micrographs of hematoxylin/eosin stained ileum sections as a function of treatment as
described in Figure 3. Ileum tissue from control mice shows a well-formed villi structure and
normal goblet cells. Neither treatment with Dox nor either dosage of pentyl PABC-Doxaz
resulted in visible damage. This is in contrast to the literature reports in which treatment with
irinotecan resulted in significant damage to the ileum, such as loss of villi and severe
disorganization of the tissue, as well as cellular vacuolar damage. The bar indicates 150 µm.
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Scatter plots of data from NCI 60-Tumor Panel. Growth data for 1938 measurements of Dox
(A), 2 measurements of Doxaz (B), and 2 measurements of PPD (C) are shown. The log of the
CES2 mRNA expression from 6 selected microarray experiments are also shown (D). The full
panel is subdivided into tissue subpopulations. Each point represents the average value of all
available measurements for a single cell line. The bars represent the average ± the standard
error of the mean for all cell lines in each population.
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Prediction of PPD response by incorporating dependence on both CES2 and Doxaz versus the
measured value in cell lines from the NCI-DTP 60-tumor panel. Error bars on the measured
bars are the standard deviation while those on the calculated bars are the calculated deviations,
determined through propagation of errors.
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Synthesis of pentyl PABC-Doxaz (PPD) from doxorubicin and equations showing the
transformation of prodrugs PPD, capecitabine, and irinotecan to active drugs, doxazolidine
(Doxaz), 5-fluorouracil, and SN-38, respectively.
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Table 1
Results of Multiple Regression Analysis of Cell IC50 Data and CES2 expression data.
Equation
Log PPD IC50 = C1(Log Doxaz IC50) − C2(Log CES2 mRNA) + C3
Terms
C1 C2 C3
0.52 ± 0.10 3.20 ± 0.53 6.59 ± 1.43
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